REVENUE (Tables)

3 Months Ended

Sep. 30, 2023

Disaggregation of Revenue [Line Items]

Financing Receivable, Allowance for Credit Loss [Table Text Block]

The rollforward for the allowance for credit losses for the nine months ended September 30, 2023, is as follows:

	Accounts Receivable		Unbilled Services		Note and Other Receivables		Total
Balance as of December 31, 2022	$	30.7	$	10.5	$	0.7	$	41.9
Plus, credit loss expense	6.2		—		—		6.2
Less, write offs	(4.1)		(1.6)		—		(5.7)
Balance as of September 30, 2023	$	32.8	$	8.9	$	0.7	$	42.4

Contract with Customer, Asset and Liability [Table Text Block]

	September 30, 2023		December 31, 2022
Dx accounts receivable	$	1,160.0	$	1,046.9
BLS accounts receivable	829.8		769.3
Less BLS allowance for doubtful accounts	(32.8)		(30.7)
Accounts receivable	$	1,957.0	$	1,785.5
Gross unbilled services	$	116.9	$	222.3
Less reserve for unbilled services	(8.9)		(10.5)
Unbilled services	$	108.0	$	211.8
Unearned revenue	$	360.8	$	310.6

Disaggregation of Revenue [Table Text Block]

The Company's revenues by segment and by payers/customer groups for the three and nine months ended September 30, 2023, and 2022, were as follows:

	For the Three Months Ended September 30, 2023								For the Three Months Ended September 30, 2022
	North America		Europe		Other		Total		North America		Europe		Other		Total
Payer/Customer
Dx
Clients	24	%	—	%	—	%	24	%	23	%	—	%	—	%	23	%
Patients	9	%	—	%	—	%	9	%	8	%	—	%	—	%	8	%
Medicare and Medicaid	8	%	—	%	—	%	8	%	8	%	—	%	—	%	8	%
Third party	36	%	—	%	—	%	36	%	38	%	—	%	—	%	38	%
Total Dx revenues by payer	77	%	—	%	—	%	77	%	77	%	—	%	—	%	77	%
BLS
Pharmaceutical, biotechnology and medical device companies	10	%	9	%	4	%	23	%	10	%	9	%	4	%	23	%
Total revenues	87	%	9	%	4	%	100	%	87	%	9	%	4	%	100	%

	For the Nine Months Ended September 30, 2023								For the Nine Months Ended September 30, 2022
	North America		Europe		Other		Total		North America		Europe		Other		Total
Payer/Customer
Dx
Clients	24	%	—	%	—	%	24	%	22	%	—	%	—	%	22	%
Patients	9	%	—	%	—	%	9	%	8	%	—	%	—	%	8	%
Medicare and Medicaid	8	%	—	%	—	%	8	%	8	%	—	%	—	%	8	%
Third party	36	%	—	%	—	%	36	%	39	%	—	%	—	%	39	%
Total Dx revenues by payer	77	%	—	%	—	%	77	%	77	%	—	%	—	%	77	%
BLS
Pharmaceutical, biotechnology and medical device companies	10	%	9	%	4	%	23	%	10	%	9	%	4	%	23	%
Total revenues	87	%	9	%	4	%	100	%	87	%	9	%	4	%	100	%

Revenues in the U.S. were $2,550.6 (83.4%) and $2,392.4 (83.5%) for the three months ended September 30, 2023, and 2022, respectively, and for the nine months ended September 30, 2023, and 2022, were $7,645.0 (83.8%) and $7,454.0 (83.4%), respectively.